Jonathan S Brammeld
Overview
Explore the profile of Jonathan S Brammeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pfeifer M, Brammeld J, Price S, Pilling J, Bhavsar D, Farcas A, et al.
Commun Biol
. 2024 Apr;
7(1):497.
PMID: 38658677
Most lung cancer patients with metastatic cancer eventually relapse with drug-resistant disease following treatment and EGFR mutant lung cancer is no exception. Genome-wide CRISPR screens, to either knock out or...
2.
Petljak M, Alexandrov L, Brammeld J, Price S, Wedge D, Grossmann S, et al.
Cell
. 2019 Mar;
176(6):1282-1294.e20.
PMID: 30849372
Multiple signatures of somatic mutations have been identified in cancer genomes. Exome sequences of 1,001 human cancer cell lines and 577 xenografts revealed most common mutational signatures, indicating past activity...
3.
Iorio F, Garcia-Alonso L, Brammeld J, Martincorena I, Wille D, McDermott U, et al.
Sci Rep
. 2018 May;
8(1):6713.
PMID: 29713020
Cancer hallmarks are evolutionary traits required by a tumour to develop. While extensively characterised, the way these traits are achieved through the accumulation of somatic mutations in key biological pathways...
4.
Brammeld J, Petljak M, Martincorena I, Williams S, Alonso L, Dalmases A, et al.
Genome Res
. 2017 Feb;
27(4):613-625.
PMID: 28179366
Drug resistance is an almost inevitable consequence of cancer therapy and ultimately proves fatal for the majority of patients. In many cases, this is the consequence of specific gene mutations...